期刊文献+

Electrohydrodynamic Fabrication of Triple-layered Polycaprolactone Dura Mater Substitute with Antibacterial and Enhanced Osteogenic Capability

原文传递
导出
摘要 In the field of dura mater repair,it is essential to employ artificial substitutes mimicking the multilayered microar-chitecture and multiple functions of native dura mater for effective neurosurgery.However,existing artificial dura mater substitutes commonly cause complications because of mismatched structural and mechanical properties as well as the lack of antibacterial activity or osteogenic capability.In this study,a triple-layered dura mater substi-tute was fabricated by electrohydrodynamic(EHD)jetting techniques,including electrospinning and melt-based EHD printing processes.Highly aligned polycaprolactone(PCL)nanofibers loaded with gentamicin sulfate(GS)were prepared by electrospinning to form the inner layer,which can mimic the aligned collagen fibers of the native dura mater.Random PCL-GS nanofibers were then deposited by electrospinning to form the middle layer.They were intended to enhance the mechanical properties of the fabricated scaffolds.The outer layer involv-ing PCL microfibers doped with nano-hydroxyapatite(nHA)at various angles was printed by the melting-based EHD method,which can enhance osteogenic capability and promote the fusion between the dura mater substi-tute and the skull.The tensile strength of the triple-layered drug-loaded biomimetic dura mater substitute was 22.42±0.89 MPa,and the elongation at break was 36.43%±2.00%.The addition of GS endowed the substitutes with an anti-infection property without influencing their cytocompatibility.Furthermore,the incorporation of nHA promoted the osteogenic differentiation of MC3T3-E1 cells seeded on the triple-layered scaffolds.This work offers a promising strategy to manufacture multilayered dura mater substitutes with the desired antibacterial and enhanced osteogenic capability performance,possibly providing a novel candidate for dural tissue repair.
出处 《Chinese Journal of Mechanical Engineering(Additive Manufacturing Frontiers)》 2022年第2期66-75,共10页 中国机械工程学报(增材制造前沿)(英文)
基金 supported by National Key Research and Develop-ment Program of China(Grant No.2018YFA0703000) OPEN Project(Grant No.BHJ17C019),National Natural Science Foundation of China(Grant No.52125501) Key Research Project of Shaanxi Province(Grant Nos.2020GXLH-Y-021,2021GXLH-Z-028) Guangdong Basic and Ap-plied Basic Research Foundation(Grant No.2020B1515130002) Inno-vation Cultivation Fund of the Sixth Medical Center of PLA General Hos-pital(Grant No.CXPY201913) China Postdoctoral Science Foundation Funded Project(Grant No.2021M702597) Youth Innovation Team of Shaanxi Universities and the Fundamental Research Funds for the Central Universities.
  • 相关文献

参考文献3

二级参考文献22

  • 1Greenberg MS. Handbook of Neurosurgery, 7 ed. New York: Thieme; 2010: 342.
  • 2Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts: a systematic review. J Neurosurg Pediatr 2008; 1: 48-56.
  • 3Bayston R, de Louvois J, Brown EM, Johnston RA, Lees P, Pople IK. Use of antibiotics in penetrating craniocerebral injuries. "Infection in Neurosurgery" Working Party of British Society for Antimicrobial Chemotherapy. Lancet 2000; 355: 1813-1817.
  • 4Sonabend AM, Korenfeld Y, Crisman C, Badjatia N, Mayer SA, Connolly ES Jr. Prevention of ventriculostomy-related infections with prophylactic antibiotics and antibiotic-coated external ventricular drains: a systematic review. Neurosurgery 2011; 68: 996-1005.
  • 5Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346: 334-339.
  • 6Rouveix B. Antibiotic safety assessment. Int J Antimicrob Agents 2003; 21: 215-221.
  • 7Narotam PK, van Dellen JR, Bhoola KD. A clinicopathological study of collagen sponge as a dural graft in neurosurgery. J Neurosurg 1995; 82: 406-412.
  • 8Reddy M, Schoggl A, Reddy B, Saringer W, Weigel G, Matula C. A clinical study of a fibrinogen-based collagen fleece for dural repair in neurosurgery. Acta Neurochir (Wien) 2002; 144: 265- 269.
  • 9CLSI. 2012. Performance standards for antimicrobial susceptibility testing; Twenty-second informational supplement. M100-,&22, 2012; 32: 72-78.
  • 10Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. USFDA, 2000. (Accessed March 4, 2013 at http://wwwjda.gov/ downloadslDrugslGuidanceComplianceRegulatorylnformationl GUidances/UCM070246.pdj).

共引文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部